UBA1 and VEXAS syndrome: In our cohort of patients with suspected VEXAS who underwent both Sanger sequencing and NGS, no UBA1 variants were identified by NGS in samples classified as negative by Sanger sequencing, supporting its potential as a cost-effective and more accessible alternative.